Skip to content

Peptides, hormones and pipeline drugs

Survodutide

Survodutide is an investigational weekly injection from Boehringer Ingelheim and Zealand Pharma that activates both the glucagon and GLP-1 receptors.

Clinician review pending Updated Peptides, hormones and pipeline drugs
DefinitionSurvodutide is an investigational weekly injection from Boehringer Ingelheim and Zealand Pharma that activates both the glucagon and GLP-1 receptors.

What it means

Survodutide is a dual agonist of the glucagon and GLP-1 receptors. The GLP-1 part reduces appetite, while the glucagon part may increase energy use and fat burning in the liver. That has made it a candidate for both obesity and fatty liver disease (MASH).

Its phase 3 program is called SYNCHRONIZE. In 2026 the companies reported that adults with obesity or overweight without diabetes lost up to about 16.6% of body weight on average at 76 weeks, compared with about 3.2% on placebo, using an analysis that assumes people stayed on treatment. A trial in people with type 2 diabetes reported smaller average losses.

Survodutide was not FDA-approved at our last review. The companies said they planned to file for approval in 2027. Stomach side effects were the most common in trials.

Why it matters

Survodutide tests whether adding glucagon to GLP-1 helps weight and liver health, a question that shapes several pipeline drugs.

Related terms

Glucagon receptor agonistDual agonistEfficacy estimandMazdutide

Sources

  1. ClinicalTrials.gov: survodutide studies

Clinician review pending. Drafted from primary sources and waiting for sign-off by a licensed clinician (MD, DO or PharmD) before launch. Every number is checked against its source. Drug facts are re-checked quarterly, prices monthly and whenever a label changes. How we review · Report an error